-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Covid-19 ger allt snabbare insjuknande – omikron kortar inkubationstiden
Sedan virusvarianten omikron blev helt dominerade i spridningen av covid-19 har inkubationstiden sjunkit kraftigt, till bara drygt tre dygn, enligt en ny metastudie.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
NT-rådet rekommenderar Opdivo i kombination med Yervoy vid kolorektalcancer
NT-rådet rekommenderar immunterapibehandling med Opdivo i kombination med Yervoy för behandling av metasterande kolorektalcancer.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING